US5849331A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Incorporation of biological molecules into bioactive glasses
Assignee: University of Pennsylvania
•
Filing: 1997-09-03
•
Granted: 1998-12-15
•
Expires: 2017-09-03
Abstract
Abstract Carriers comprising silica-based glass providing for the controlled release of biologically active molecules, their methods of preparation, and methods of use are disclosed. The carriers are prepared using a sol-gel-derived process. Biologically active molecules are incorporated within the matrix of the glass during production.
Inventors
- 👤 Paul Ducheyne
- 👤 Shulamith Radin
- 👤 Erick Manuel Santos
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:15
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/14; A61F; A61F2/00; A61F2/02; A61F2/28; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K38/55; A61K38/57; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1611; A61K9/20; A61K9/2004; A61K9/2009; A61L; A61L27/00; A61L27/28; A61L27/30; A61L27/306; A61L27/50; A61L27/54; C; C03; C03C; C03C4/00; C03C4/0007; A61F2/30; A61F2/30767; A61F2002/30001; A61F2002/30667; A61F2002/30677; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/402; A61L2300/404; A61L2300/406; A61L2300/41; A61L2300/412; A61L2300/414; A61L2300/60; A61L2300/602; A61L2430/00; A61L2430/02
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
39 words
A method for delivering biological molecules to a bony defect without burst effect comprising implanting a controlled-release carrier comprising silica-based glass having a porous matrix and biologically active molecules incorporated throughout said matrix of said glass into said defect.
Claim 2
Independent Claim
39 words
A method for delivering biological molecules to a bony defect without burst effect comprising implanting a controlled-release carrier comprising silica-based glass having a porous matrix and biologically active molecules incorporated throughout said matrix of said glass into said defect.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein said glass is bioactive.
Claim 4
Dependent Claim
23 words
The method of claim 1 wherein said biologically active molecule comprises from about 0.0001 to about 10 percent of said carrier by weight.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said biologically active molecules comprise a drug.
Claim 6
Dependent Claim
11 words
The method of claim 4 wherein said drug comprises an antibiotic.
Claim 7
Dependent Claim
10 words
The method of claim 5 wherein said antibiotic is vancomycin.
Claim 8
Dependent Claim
23 words
The method of claim 1 wherein said carrier is in the form of a coating on an implant for filling said bony defect.
Claim 9
Dependent Claim
12 words
The method of claim 7 wherein said implant is in granular form.
Claim 10
Dependent Claim
12 words
The method of claim 7 wherein said implant is a prosthetic device.
Claim 11
Dependent Claim
12 words
The method of claim 4 wherein said drug is a growth factor.
Claim 12
Dependent Claim
11 words
The method of claim 10 wherein said growth factor is TGF-β.
Claim 13
Dependent Claim
12 words
The method of claim 4 wherein said drug is an anti-inflammatory agent.
Claim 14
Dependent Claim
11 words
The method of claim 4 wherein said drug is an analgesic.
Claim 15
Dependent Claim
18 words
The method of claim 1 wherein said biologically active molecules are delivered at a steady state upon implantation.
Claim 16
Dependent Claim
32 words
The method of claim 14 wherein said carrier is immersed in a solution with ion content similar to interstitial fluid for a period of up to about seven days prior to implantation.
Claim 17
Independent Claim
40 words
A method for sustained delivery of an antibiotic in situ without burst effect comprising contacting a controlled-release carrier comprising silica-based glass having a porous matrix and at least one antibiotic incorporated throughout said matrix of said glass with a sample.
Claim 18
Independent Claim
40 words
A method for sustained delivery of an antibiotic in situ without burst effect comprising contacting a controlled-release carrier comprising silica-based glass having a porous matrix and at least one antibiotic incorporated throughout said matrix of said glass with a sample.
Claim 19
Dependent Claim
10 words
The method of claim 16 wherein said glass is bioactive.
Claim 20
Dependent Claim
23 words
The method of claim 16 wherein said biologically active molecule comprises from about 0.0001 to about 10 percent of said carrier by weight.
Claim 21
Dependent Claim
12 words
The method of claim 16 wherein said carrier is in granular form.
Claim 22
Dependent Claim
12 words
The method of claim 16 wherein said carrier is in disc form.
Claim 23
Dependent Claim
10 words
The method of claim 16 wherein said antibiotic is vancomycin.
References Cited (Backward Citations)
DE2735754A1
Cited
DE3134728A1
Cited
US4851150A
Cited
DD222498A1
Cited
US4775646A
Cited
US4772203A
Cited
DD248351A1
Cited
US4563350A
Cited
US4613516A
Cited
US4849378A
Cited
US4859525A
Cited
US4851046A
Cited
US4869906A
Cited
DE3905394A1
Cited
US5344654A
Cited
US5108436A
Cited
US5207710A
Cited
US5204106A
Cited
US4976736A
Cited
WO1993005823A1
Cited
US5371018A
Cited
US5074916A
Cited
EP0462608A1
Cited
US5374427A
Cited
WO1992007554A1
Cited
GB2255907A
Cited
US5200334A
Cited
US5270300A
Cited
US5464450A
Cited
US5356635A
Cited
JPH05253286A
Cited
US5643789A
Cited
EP0616814A1
Cited
US5591453A
Cited
US5702717A
Cited
US5711958A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-12-14 | 2002-06-15 | 2002-12-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-12-14 | 2006-06-15 | 2006-12-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-12-14 | 2010-06-15 | 2010-12-15 | $7700.00 | Window Closed / Lapsed |